Evacetrapib

EVACETRAPIB A hope in order to treat cardiovascular disease… Laurent MAGNIES Claire JAGODZINSKI

INTRODUCTION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],JAMA – Nov16, 2011 – Vol 306 – N°19

Lipid Exchange ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Journal of Lipid Research – Vol 52 – Sept 25, 2011

CETP Activity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Journal of Lipid Research – Vol 52 – Sept 25, 2011

Preclinical Studies (1) ,[object Object],[object Object],[object Object],[object Object],Journal of Lipid Research – Vol 52 – Sept 25, 2011

Preclinical Studies (2) ,[object Object],[object Object],[object Object],[object Object],[object Object],Journal of Lipid Research – Vol 52 – Sept 25, 2011

Journal of Lipid Research – Vol 52 – Sept 25, 2011

Preclinical Studies (2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Journal of Lipid Research – Vol 52 – Sept 25, 2011

Clinical Trial: April 2010 to Jan 2011 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],JAMA – Nov16, 2011 – Vol 306 – N°19

Torcetrapib (Pfizer) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Journal of Lipid Research – Vol 52 – Sept 25, 2011

Study Design RANDOMIZATION Monotherapy Combination with statins Evacetrapib 100mg N = 398 PLACEBO n = 38 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Clinic Visits and Laboratory Tests ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],JAMA – Nov16, 2011 – Vol 306 – N°19

Monotherapy Average lipid levels at the beginning: LDL-C: 144.3mg/dL HDL-C: 55.1 mg/dL TG : 121.3 mg/dL JAMA – Nov16, 2011 – Vol 306 – N°19 . . . .

Combination with statin therapy JAMA – Nov16, 2011 – Vol 306 – N°19 . . . .

Results ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],JAMA – Nov16, 2011 – Vol 306 – N°19

Safety Data JAMA – Nov16, 2011 – Vol 306 – N°19

Adverse Events ,[object Object],[object Object],[object Object],[object Object],JAMA – Nov16, 2011 – Vol 306 – N°19

CONCLUSION (1) ,[object Object],[object Object],[object Object],[object Object],[object Object],JAMA – Nov16, 2011 – Vol 306 – N°19

CONCLUSION (2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Evacetrapib

Recommended

Recommended

More Related Content

What's hot

What's hot (19)

Similar to Evacetrapib

Similar to Evacetrapib (20)

Evacetrapib

Editor's Notes